Upgrade to SI Premium - Free Trial

Regeneron Pharmaceuticals (REGN) Posts Q4 Loss of 37c/Share

February 13, 2012 7:01 AM
Regeneron Pharma
ceuticals, Inc. (NASDAQ: REGN) reported Q4 EPS of ($0.37), $0.23 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $123 million versus the consensus estimate of $131.04 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.

Categories

Earnings